Beddow Capital Management Inc. Sells 8,181 Shares of Pfizer Inc. (NYSE:PFE)

Beddow Capital Management Inc. lowered its holdings in Pfizer Inc. (NYSE:PFE) by 4.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 162,379 shares of the biopharmaceutical company’s stock after selling 8,181 shares during the period. Pfizer makes up about 1.8% of Beddow Capital Management Inc.’s portfolio, making the stock its 24th largest holding. Beddow Capital Management Inc.’s holdings in Pfizer were worth $4,308,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of PFE. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer in the 4th quarter valued at approximately $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer in the 4th quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer in the 4th quarter valued at approximately $28,000. Noble Wealth Management PBC acquired a new position in shares of Pfizer in the 4th quarter valued at approximately $31,000. Finally, Curio Wealth LLC acquired a new position in shares of Pfizer in the 4th quarter valued at approximately $32,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on PFE. Bank of America restated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Truist Financial lowered their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Citigroup lowered their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Insider Activity

In other news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Trading Up 0.1 %

PFE opened at $26.20 on Friday. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market capitalization of $148.61 billion, a price-to-earnings ratio of 18.58, a PEG ratio of 0.64 and a beta of 0.61. The company’s 50 day moving average price is $26.17 and its two-hundred day moving average price is $27.05.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the firm posted $0.10 EPS. The company’s quarterly revenue was up 24.7% on a year-over-year basis. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.